Acotec Scientific Holdings Limited (HK:6669)
:6669
Want to see HK:6669 full AI Analyst Report?
Top Page
Acotec Scientific Holdings Limited
(6669)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$11.00
▼(-22.32% Downside)
Action:ReiteratedDate:04/29/26
The score is mainly supported by improving financial performance (better margins, modest leverage, and stronger cash conversion in 2025). Offsetting this, technical signals are clearly weak with the price below major moving averages and negative MACD, and valuation looks only fair-to-expensive on a ~31.5 P/E without a dividend yield indicated.
Positive Factors
High and improving profitability
Margin expansion to ~18.5% and sustained ~72% gross margins indicate durable product-level profitability and better operating leverage. Higher margins support reinvestment, resilience to cost pressure, and long-term ability to convert revenue gains into durable earnings and cash.
Negative Factors
Historic earnings volatility
Prior years of losses and volatile earnings show the business has cyclical or execution risks. Such volatility makes future margin and cash outcomes less predictable, increasing the importance of sustained operational execution to confirm the recent turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
High and improving profitability
Margin expansion to ~18.5% and sustained ~72% gross margins indicate durable product-level profitability and better operating leverage. Higher margins support reinvestment, resilience to cost pressure, and long-term ability to convert revenue gains into durable earnings and cash.
Read all positive factors
Acotec Scientific Holdings Limited (6669) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.07B
Dividend YieldN/A
Average Volume (3M)462.19K
Price to Earnings (P/E)31.5
Beta (1Y)1.01
Revenue Growth20.65%
EPS Growth127.07%
CountryHK
Employees650
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.11
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.48
Price to Sales (P/S)5.83
P/FCF Ratio25.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.00Price Target Upside20.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.43
Revenue Forecast (FY)HK$728.00M
Acotec Scientific Holdings Limited Business Overview & Revenue Model
Company Description
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It o...
How the Company Makes Money
null...
Acotec Scientific Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 592.85M | 627.95M | 533.99M | 473.85M | 395.55M | 303.81M |
| Gross Profit | 446.01M | 452.28M | 402.72M | 377.42M | 336.35M | 265.94M |
| EBITDA | 81.08M | 131.29M | 112.48M | 70.54M | 91.17M | -51.02M |
| Net Income | 100.90M | 116.10M | 52.28M | 14.49M | 70.14M | -79.08M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.87B | 1.66B | 1.61B | 1.41B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 995.38M | 948.37M | 809.57M | 879.21M | 986.46M | 1.14B |
| Total Debt | 236.13M | 244.49M | 202.92M | 234.00M | 47.78M | 24.57M |
| Total Liabilities | 384.00M | 392.18M | 312.76M | 314.53M | 134.46M | 100.17M |
| Stockholders Equity | 1.44B | 1.48B | 1.35B | 1.30B | 1.28B | 1.21B |
Cash Flow | ||||||
| Free Cash Flow | 159.00M | 145.46M | 5.31M | -92.54M | -115.45M | -31.72M |
| Operating Cash Flow | 194.51M | 167.32M | 102.79M | -12.88M | -68.75M | -10.48M |
| Investing Cash Flow | -203.20M | -527.16M | 45.02M | -319.22M | -49.17M | -20.48M |
| Financing Cash Flow | -35.32M | 24.79M | -35.24M | -23.21M | -32.87M | 1.02B |
Acotec Scientific Holdings Limited Technical Analysis
Negative
14.16
Price Trends
12.63
Negative
13.02
Negative
12.64
Negative
Market Momentum
-0.13
Positive
42.22
Neutral
22.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Negative. The current price of 14.16 is above the 20-day moving average (MA) of 12.22, above the 50-day MA of 12.63, and above the 200-day MA of 12.64, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 42.22 is Neutral, neither overbought nor oversold. The STOCH value of 22.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6669.
Acotec Scientific Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$2.11B | 22.44 | 4.25% | ― | 47.07% | ― | |
59 Neutral | HK$3.07B | 31.51 | 7.22% | ― | 20.65% | 127.07% | |
53 Neutral | HK$820.28M | -0.88 | -21.05% | ― | -34.96% | 43.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$4.27B | -18.13 | -11.27% | ― | 16.35% | 9.43% | |
44 Neutral | HK$3.36B | 17.15 | 2.04% | ― | 90.81% | ― | |
43 Neutral | HK$3.15B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:6669
Acotec Scientific Holdings Limited
9.80
1.72
21.29%
HK:9996
Peijia Medical Ltd.
6.36
1.05
19.77%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.47
-2.03
-45.11%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.97
1.74
27.93%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.86
-0.69
-27.06%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
54.30
24.85
84.38%
Acotec Scientific Holdings Limited Corporate Events
Acotec Scientific to Revamp Constitution for Virtual Meetings and Treasury Shares
Mar 26, 2026
Acotec Scientific Holdings Limited plans to amend its Memorandum and Articles of Association and adopt a new consolidated version to align with updated Hong Kong listing requirements and shareholder protection standards. The move includes enabling...
Acotec Scientific Boosts 2025 Profit on New Approvals and Diversified Device Portfolio
Mar 26, 2026
Acotec Scientific reported strong growth for 2025, with revenue rising 20.7% to RMB644.6 million and profit for the year surging 128.0% to RMB119.2 million, driven by diversified product revenue and improved operational efficiency. Core products g...
Acotec Scientific Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Acotec Scientific Holdings Limited has scheduled a board meeting for March 26, 2026 to review and approve the audited annual results for the financial year ended December 31, 2025. At the same meeting, the board will also consider the publication ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.